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Purpose: This study was designed to investigate the relationship between serum relaxin 
concentration (SRC) and menstrual history and hormonal contraceptive use among elite 
collegiate female athletes. Evaluation of SRC in athletes is necessary, because relaxin has been 
  associated with increased knee joint laxity and decreased anterior cruciate ligament (ACL) 
strength in animal models.
Methods: National Collegiate Athletic Association Division I female athletes participating 
in sports at high risk for ACL tears – basketball, field hockey, gymnastics, lacrosse, soccer, 
and volleyball – were invited to participate. All participants completed a questionnaire about 
their menstrual history and hormonal contraceptive use. Venipuncture was performed to obtain 
samples of serum progesterone and relaxin. Samples were obtained during the mid-luteal phase 
from ovulating participants, and between the actual or projected cycle days 21 to 24, from 
anovulatory participants. Serum concentration of relaxin and progesterone was determined 
by ELISA and the data were analyzed using SPSS statistical software with significance set 
at P = 0.05.
Results: 169 female athletes participated. The mean SRC among all participants was 
3.08 ± 6.66 pg/mL). The mean SRC differed significantly between those participants using 
hormonal contraceptives (1.41 pg/mL) and those not using hormonal contraceptives (3.08 pg/mL, 
P = 0.002). Mean SRC was lowest among amenorrheic participants (1.02 pg/mL) and highest 
among oligomenorrheic participants (3.71 pg/mL) and eumenorrheic participants (3.06 pg/mL); 
these differences were not significant (P = 0.53). Mean serum progesterone concentration (SPC) 
differed significantly between those participants using hormonal contraceptives (2.80 ng/mL), 
and those not using hormonal contraceptives (6.99 ng/mL, P , 0.0001).
Conclusions: There is a positive correlation between serum progesterone and SRC and an 
attenuation of SRC with hormonal contraceptive use. Our results underscore the significant 
role that hormonal contraceptives can play in decreasing relaxin levels, if future investigations 
establish a link between relaxin levels and ligamentous injury among female athletes.
Keywords: hormones, ACL, anterior cruciate ligament, hormonal contraceptives, menstrual 
cycle
Introduction
Relaxin is a peptide hormone that belongs to the insulin superfamily of hormones.1,2 
Recent research on this hormone has revealed that it has three forms in humans,3 which 
have unique sites of production4–6 and a broad range of physiologic effects throughout 
the body. The focus of this study is on Relaxin-2, which is produced by the corpus 
luteum,7 decidua,8–10 and placenta6,10 and is transcriptionally regulated by progesterone 
and glucocorticoid hormones.11 Relaxin-2 has historically been studied in pregnant International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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women. Because it is also found in the serum of   nonpregnant 
women,12–14 its effects on nonreproductive tissue merits 
further investigation.
Research has established that the function of Relaxin-2 
is to facilitate the remodeling of collagen through the 
upregulation of collagenases,15,16 matrix metalloproteinases,17 
and tissue plasminogen activator (tPA).15,17 Because of its 
well-established role as a female reproductive   hormone, the 
collagenolytic effects of Relaxin-2 have been studied primarily 
with respect to its effect on pregnancy and parturition,18,19 
myometrial pathology,20 urinary incontinence,21 and premen-
strual dysphoric disorder22 in middle-aged women. More 
recently, a number of studies have begun to investigate the 
role of relaxin in nonreproductive organ and tissue disease 
processes.23–26
Relaxin has been associated with increased knee joint 
laxity in pregnant women27 and decreased anterior cruciate 
ligament (ACL) strength in animal models.28 The established 
presence of relaxin receptors on the female ACL29,30 also 
underscores that relaxin-mediated remodeling of female 
  ligaments is an important mechanism to investigate. To date, 
no studies have described the serum relaxin concentration 
(SRC) among a large sample of young, healthy, nulligravidae 
elite female athletes. Understanding SRC among this 
  population is important, because relaxin has been shown to 
increase ligament laxity among women.27,31,32
This study was designed to investigate the   relationship 
between SRC and menstrual history and hormonal 
contraceptive use among elite collegiate female athletes. 
Our hypothesis is that athletes who are on hormonal 
contraceptives, or who are amenorrheic, will have sig-
nificantly lower levels of relaxin than those who are not on 
hormonal contraceptives or those who are eumenorrheic or 
oligomenorrheic, because these athletes will be anovulatory 
and not producing the corpus luteum thought to be necessary 
to secrete Relaxin-2.
Methods
After institutional review board approval was obtained, 
National Collegiate Athletic Association Division I female 
athletes who participate in sports identified as high risk for 
ACL tears – basketball, field hockey, gymnastics, lacrosse, 
soccer, and volleyball – were recruited to participate. Athletes 
with a history of pregnancy were ineligible to participate. 
Of the approximately 190 eligible athletes, 169 agreed to 
participate (89% response rate). The desired sample size was 
at least 90, to reach 80% power to detect a 10% difference 
in mean SRC between 2 groups.
All participants completed a questionnaire on their 
  demographic information, menstrual history, pregnancy 
history, and hormonal contraceptive use. This information 
was verified by review of participant medical records. 
Urine luteinizing hormone (LH) testing was used to   confirm 
when to obtain blood samples from the participants, 
because samples had to be obtained during the mid-luteal 
phase of the menstrual cycle when relaxin is known to 
peak.8,13   Participants who reported being eumenorrheic 
(10–12 menstrual   periods per year) or oligomenorrheic 
(5–9 menstrual   periods per year), and who were not on 
any form of hormonal contraception, underwent self-
testing with urine LH detection tests (Ovulation Midstream 
Tests,   Early-pregnacy-tests.com, Bellingham, WA, USA) 
to   determine the date of their LH surge. LH testing was 
conducted for 5 days on average starting 2 days before the 
anticipated date of ovulation. If a positive LH test was not 
obtained during the first round of testing, more tests were 
given for a longer timeframe   during the subsequent men-
strual cycle and the testing start date was adjusted, based 
on the newly determined cycle length. Once participants 
had reported a positive LH test, they were scheduled for a 
blood draw 7 to 10 days after the date of the positive LH 
test, which is the mid-luteal window when the relaxin surge 
is expected to occur.
Participants who reported being amenorrheic (4 or fewer 
menstrual cycles per year) did not undergo LH testing since 
they were assumed to be anovulatory. Instead, amenorrheic 
participants were scheduled for a blood draw 21 to 24 days 
after they were projected to have had their last menstrual period 
(LMP). The projected day zero of their LMP was based on a 
forward calculation of assuming regular cycles from their last 
confirmed LMP. Participants who reported being on a form 
of hormonal contraception to suppress ovulation, regardless 
of their menstrual history, were scheduled to have their blood 
taken 21 to 24 days after the start of their LMP. Urine preg-
nancy tests (hCG Midstream Tests, Early-  pregnacy-tests.com, 
Bellingham, WA, USA) were given when blood was taken, to 
verify that participants were not pregnant.
Venipuncture was performed using a BD Vacutainer 
Blood Collection System and approximately 3 to 4 mL of 
blood was collected. The plasma sample was left standing 
undisturbed at room temperature for 30 minutes to allow 
for adequate clotting. The sample was then placed in a 
centrifuge (Quest Diagnostics VanGuard V6500, Madison, 
NJ, USA) and spun for 15 minutes at 3000 rpm to separate 
the serum and blood cell layers. After centrifugation, the 
serum was extracted by pipette and aliquotted into two 1-mL International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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samples in Nalgene vials. All serum samples were coded 
with unique identifiers to ensure that the lab technician was 
blinded to their content. All samples were stored at 80°C 
until analysis.
A Quantikine Human Relaxin-2 Immunoassay (DRL200, 
R&D Systems Inc., Minneapolis, MN, USA) was used 
according to the manufacturer’s protocol to determine 
the SRC of the samples. The intra-assay and inter-assay 
coefficients of variation for mean SRC (34.4 pg/mL and 
40.8 pg/mL) were 4.7% and 10.2%, respectively. The mean 
minimum detectable dose was 1 pg/mL. All samples were 
run in triplicate and serum relaxin concentration values were 
calculated based on the standard curve, including the zero 
dose standard. The assay utilized the standard quantitative 
sandwich enzyme immunoassay technique.
A Progesterone ELISA (BQ 129S, BioQuant, San Diego, 
CA, USA) was used to determine the progesterone 
concentrations in the samples in order to verify that those 
who were on hormonal contraceptives did not have   ovulatory 
cycles. The intra-assay and inter-assay coefficients of 
  variation for mean progesterone concentration (1.72 ng/mL 
and 2.16 ng/mL) were 5.36% and 9.68%, respectively. All 
samples were run in duplicate according to the manufacturer’s 
protocol. The threshold for determining was a progesterone 
concentration of 3.3 ng/mL, while 4.4 ng/mL was deemed 
the cut-off for determining mid-luteal phase.
ANOVA analysis was used to determine the   difference 
between mean SRC and mean progesterone, based on 
menstrual history (eumenorrheic, oligomenorrheic, and 
amenorrheic) and t tests were used to determine differences 
between groups based on hormonal contraceptive use and 
ovulatory status. Pearson correlations were done to assess 
the relationship between relaxin and progesterone, as well 
as between body mass index (BMI) and relaxin. Significance 
was set at P = 0.05.
Results
All 169 participants (23 from basketball, 24 from field 
hockey, 39 from gymnastics, 38 from lacrosse, 24 from 
soccer, and 21 from volleyball) provided adequate blood 
samples for analysis. The mean age of participants was 
19.49 ± 1.34 years. The mean BMI was 22.42 ± 1.83. 
There was no significant correlation between BMI and SRC 
(r = 0.02, P = 0.81) and no significant correlation between 
BMI and progesterone levels (r = 0.03, P = 0.67). Overall, 
the majority (123, 72.8%) of participants were eumenorrheic, 
36 (21.3%) were oligomenorrheic, and 10 (5.9%) were 
amenorrheic. The majority (99, 58.6%) of participants 
were not using a hormonal form of contraceptive compared 
with the 70 (41.4%) who were using a form of hormonal 
contraceptive. Of the women on hormonal contraceptives, 
the vast majority used   combination oral contraceptive (COC) 
pills, 2 were using the NuvaRing, and 1 was on a progesterone-
only contraceptive pill (Nora-BE). Of   participants on COCs, 
66% were on either Yasmin, Orthotricyclen Lo, Loestrin, or 
Trinessa, and the remainder were on either Zovia, Alesse, 
Desogen, Enpresse, Kavina, Diane-35, Ovcon, Fecon, 
Microgestin, OrthoEvra, Mycrogynon, TriSpintec, or Junel. 
Within the hormonal contraceptive-using group, 4 (6%) were 
amenorrheic, 19 (29%) were oligomenorrheic, and 43 (65%) 
were eumenorrheic.
The mean SRC among all participants was 3.08 ± 
6.66 pg/mL (range, 0–50.38 pg/mL). Three participants 
had SRCs greater than 1 standard deviation (SD) above 
the mean (.9.11 pg/mL), 3 had SRCs greater than 2 SDs 
above the mean (.15.77 pg/mL), and 2 had SRCs greater 
than 3 SDs above the mean (.22.43). As outlined in 
Table 1, there was a significant difference between the mean 
SRC among   participants using hormonal contraceptives 
(1.41 ± 3.50 pg/mL) compared with those not using hormonal 
contraceptives (4.25 ± 8.02 pg/mL, P = 0.002). ANOVA 
  analysis revealed no statistically significant difference in 
mean SRC between the participants based on menstrual 
history (P = 0.53). However, the mean SRC was lowest among 
amenorrheic participants (1.02 ± 2.47 pg/mL) and highest 
among oligomenorrheic participants (3.71 ± 8.86 pg/mL) 
and eumenorrheic participants (3.06 ± 6.14 pg/mL). Among 
the women not using hormonal contraceptives, there was 
a significant difference in SRC (P = 0.003) and in serum 
progesterone concentration (SPC) (P , 0.0001) when 
  analyzed by ovulatory status.
The mean serum progesterone concentration (SPC) 
among all participants was 5.25 ± 4.58 ng/mL (range, 
1.09–18.84 ng/mL). There was a significant difference 
between mean SPC among participants using hormonal con-
traceptives (2.80 ± 1.76 ng/mL) versus participants not using 
hormonal contraceptives (6.99 ± 5.15 ng/mL, P , 0.0001). 
ANOVA analysis revealed no significant   difference in mean 
SPC between participants based on menstrual history alone 
(P = 0.45). The mean SPC was lowest among amenorrheic 
participants (3.53 ± 2.20 ng/mL), second lowest among 
  oligomenorrheic participants (5.13 ± 4.93 ng/mL), and highest 
among eumenorrheic participants (5.43 ± 4.62 ng/mL). In the 
hormonal contraceptive group, 21 participants (30%) had SPCs 
above the 3.3 ng/mL threshold for determining   ovulation. 
Of the participants not using hormonal contraception, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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28% had SPCs below the 3.3 ng/mL cutoff for ovulatory 
cycles; 2 amenorrheic, 14 oligomenorrheic, and 17 eumenor-
rheic participants had SPCs below the 4.4 ng/ML threshold 
for determining mid-luteal phase. Lastly, as depicted in 
Table 2, there was a significant correlation overall, and 
among   noncontracepting, ovluatory, oligomenorrheic and 
eumennorheic participants, between serum progesterone 
and relaxin concentrations.
Discussion
This is the largest study to assess SRC among young, 
healthy, nulligravidae, elite collegiate female athletes. It is 
important to understand the SRC in this population because 
of the possible effect of relaxin on ligament stability among 
athletes. Since relaxin is involved in collagen remodeling, 
and collagen is an important structural element of ligaments, 
it is plausible that women with increased relaxin levels may 
have an increased risk of ligament injury, which could then 
make them more susceptible to injuries such as ACL rupture. 
Before investigating any correlation between these types of 
injuries and relaxin levels, however, further investigation of 
relaxin concentrations in this population is necessary.
We found that our sample of collegiate female   athletes 
had a relatively low range of SRCs (0–50.83 pg/mL) com-
pared with the SRCs reported by Arnold et al among a 
similar population of athletes (291–616 pg/mL).33 The SRCs 
among our athletes were also lower than those reported 
by Stewart13 among women with nonconceptive cycles 
(30–150 pg/mL). Additionally, these SRCs were lower than 
those reported among older parous women by Binder et al 
(260–620 pg/mL, Santa Cruz Biotechnology Inc. assay),23 
by Pehrrson et al (144–4500 pg/mL, Immunodiagnostix 
assay),22 and by Wreje et al (20–255 ng/L, Genentech 
reagents).34 Just as all these studies reported 1 to several 
participants with unexpectedly high SRCs, our study also 
revealed outliers. Four athletes had values greater than 1 SD 
Table 1 Mean serum relaxin concentration, serum progesterone concentration, body mass index (BMI), and participant age
Serum relaxin 
concentration 
(pg/mL)
Serum 
progesterone 
concentration 
(ng/mL)
BMI Participant age 
(years)
All participants 
(n = 169)
3.08 ± 6.66 5.25 ± 4.58 22.42 ± 1.83 19.49 ± 1.34
No hormonal 
contraceptive (n = 99)
4.25 ± 8.02* 6.99 ± 5.15** 22.35 ± 1.80 19.11 ± 1.20
Ovulatory (71) 5.30 ± 9.08a 8.79 ± 5.04b 22.28 ± 1.78 19.17 ± 1.27
nonovulatory (28) 1.61 ± 3.08a 2.42 ± 0.49b 22.27 ± 1.86 18.96 ± 1.04
Hormonal 
contraceptive (n = 70)
1.41 ± 3.50* 2.80 ± 1.76** 22.53 ± 1.90 20.01 ± 1.35
Ovulatory (21) 2.12 ± 5.39 4.88 ± 1.85c 21.99 ± 1.96 19.62 ± 1.28
nonovulatory (49) 1.11 ± 2.18 1.91 ± 0.54c 22.77 ± 1.84 20.18 ± 1.35
Amenorrheic (n = 10) 1.02 ± 2.47 3.53 ± 2.20 22.15 ± 2.22 19.10 ± 1.66
Ovulatory (4) 0.0 ± 0.0 5.47 ± 2.40 22.15 ± 2.52 19.0 ± 2.0
nonovulatory (6) 1.70 ± 3.09 2.23 ± 0.46 22.51 ± 2.24 19.17 ± 1.60
Oligomenorrheic (n = 36) 3.71 ± 8.86 5.13 ± 4.93 21.98 ± 1.61 19.42 ± 1.25
Ovulatory (17) 6.67 ± 12.13 8.48 ± 5.51d 21.86 ± 1.49 19.53 ± 1.28
nonovulatory (19) 1.05 ± 2.45 2.14 ± 0.55d 22.09 ± 1.75 19.32 ± 1.25
Eumenorrheic (n = 123) 3.06 ± 6.14 5.43 ± 4.62 22.58 ± 1.85 19.54 ± 1.34
Ovulatory (71) 4.32 ± 7.56e 7.89 ± 4.72f 22.40 ± 1.86 19.23 ± 1.24
nonovulatory (52) 1.33 ± 2.54e 2.06 ± 0.60f 22.82 ± 1.83 19.96 ± 1.36
Notes: *P = 0.002, difference in mean serum relaxin concentration (src); **P , 0.0001, difference in mean serum progesterone concentration (sPc); aP = 0.003, difference 
in mean src;  bP , 0.0001, difference in mean sPc;  cP , 0.0001, difference in mean sPc;  dP , 0.0001, difference in mean sPc;  eP = 0.003, difference in mean src;   
fP , 0.0001, difference in mean sPc.
Table  2  Pearson  correlation  between  serum  relaxin  con-
centration and serum progesterone concentration
Correlation 
coefficient (R)
P-value
Overall 0.49 ,0.01
Amenorrheic -0.13 0.71
Oligomenorrheic 0.63 ,0.01
eumenorrheic 0.44 ,0.01
Hormonal contraceptive 0.01 0.93
no hormonal contraceptive 0.50 ,0.01
Ovulatory 0.45 ,0.01
nonovulatory 0.21 0.07International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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above the mean (.9.38 pg/mL) and 3 had values greater 
than 2 SDs above the mean (.16.22 pg/mL). However, all 
samples had an SRC ,150 pg/mL, which is consistent with 
the SRCs previously reported for nonconceptive menstrual 
cycles.13 It is possible that the variation between our SRCs 
and those previously reported could be explained by a dif-
ference in the specificity of the various assays that have 
been used in these different studies. The relatively new R&D 
Systems assay (launched in August 2007) used in this study 
may be more specific for Relaxin-2, which would explain 
why our levels were lower than those previously reported. 
The R&D assay reports no significant cross-reactivity or 
interference with human insulinlike growth factor (IGF)-1, 
IGF-2, Insulin (aa 25–110), Insulin (pro) K (aa 25–110) 
N His, IGF-3, Relaxin-1, Relaxin-3. However, the majority 
of previously used assays do not report their level of specific-
ity or cross-reactivity profiles. Only a couple have reported 
having no cross reactivity with insulin,22,23 or IGF-1.23 
Lastly, this difference could also reflect a sustained increase 
in SRC among primi- or multiparous women, which makes 
their SRCs significantly higher than those of nulligravidae 
women.
Also as expected, there was a significant difference 
between mean SRC and SPC among participants who used 
hormonal contraceptives and those who did not. Hormonal 
contraceptives suppress ovulation and therefore prevent the 
formation of a corpus luteum and subsequently prevent the 
production of relaxin and progesterone. Consequently, it is 
logical that women on hormonal contraceptives would have 
lower levels of relaxin and progesterone.
The primary challenge of this study was the timing 
of the venipuncture to ensure that the serum hormone 
concentration results could be compared across groups. 
We attempted to standardize this process by having a set 
window (days 21–24) for venipuncture among the hormonal 
contraceptive group and days 7 to 10 after a positive LH test 
in those not on hormonal contraceptives. However, given 
that approximately 28% of the participants in the group not 
on hormonal contraceptives had SPCs below the 3.3 ng/mL 
threshold for determining ovulation, it is likely that they 
were either having anovulatory cycles or that the samples 
were drawn in the follicular phase. Conversely, it was also 
interesting to find that approximately 30% of participants on 
hormonal contraceptives had ovulatory cycles as indicated by 
SPC .3.3 ng/mL. This could represent a failure rate in the 
use of the hormonal contraceptives which, however, would 
be twice as high as typical use failure rates and is therefore 
unlikely to be explained completely by COC misuse. It is 
more likely that some of the higher SPCs in this group were 
from adrenally produced progesterone.
Conclusions
This study has reinforced the strong correlation between 
progesterone and relaxin levels and corpus luteum produc-
tion. The finding that hormonal contraceptive use attenuates 
serum progesterone and relaxin levels is also significant. 
Should future investigations establish a link between relaxin 
levels and ligamentous injury among women, our results 
underscore the significant role that hormonal contraceptives 
can play in decreasing relaxin levels. Future studies should 
continue to characterize the levels and behavior of relaxin 
among young nulligravidae women in addition to the 
variation in cross-reactivity and sensitivity among relaxin 
assays to improve the uniformity of SRC quantitation.
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